NEW YORK, March 19, 2026--(BUSINESS WIRE)--Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), encourages biotech and pharmaceutical companies ...

NATIONAL HARBOR, Md.--(BUSINESS WIRE)--The National Hemophilia Foundation (NHF) has officially changed its name to the National Bleeding Disorders Foundation (NBDF). Foundation leaders announced the ...

Blood clotting disorders can be inherited or acquired and lead to either excessive bleeding or too much clotting.

At Huntsman Cancer Institute, you receive expert, highly specialized care for benign bleeding and clotting disorders. Your care team includes hematologists, nurse coordinators, social workers, ...

Many people have a bleeding disorder and don't know it, but the Western Pennsylvania Bleeding Disorders Foundation is working to help people recognize the signs and get support. The foundation helps ...

Patrick Muldoon's death certificate revealed he was dealing with a type of blood disorder. Here's what to know.

COLLEGE STATION, Texas (KBTX) - The City of College Station recently recognized the month of March for National Bleeding Disorders Awareness Month, commending efforts of a Texas foundation that helps ...

Little is known about the risk of bleeding in patients with bleeding disorders who undergo major surgeries or outcomes for those managed perioperatively at hemophilia treatment centers. With ...

More than 3 million Americans have inherited bleeding disorders, and social determinants of health (SDOH) play a role in a number of ways, including cost for treatment, difficulty accessing ...

Area of focus: translational research in vascular biology, including studies on endothelial cells, platelets and other blood cells. When a patient presented with challenging nosebleeds and severe ...

Like 3 million other Americans with bleeding disorders, Tony Basa’s son Andrew relies on human plasma donors for lifesaving treatment. At age 3, Andrew received a lifestyle-altering diagnosis for an ...

Despite the considerable disease burden associated with hereditary hemorrhagic telangiectasia, no therapies are licensed for treatment. In a proof-of-concept, placebo-controlled trial, the ...